
-
Greenland PM visits Denmark as Trump threats loom
-
Philippines, US test air defences as China seizes reef
-
25 killed, fires still burning in huge Iran port blast
-
India and Pakistan troops exchange fire in Kashmir
-
Eighteen killed, fires still burning in huge Iran port blast
-
No handshake at muted India-Pakistan border ceremony
-
Maligned by Trump, White House reporters hold subdued annual gala
-
Austria trials DNA testing to uncover honey fraud
-
Trump trade war pushes firms to consider stockpiling
-
D'Backs' Suarez becomes 19th MLB player to hit four homers in one game
-
Continuity or rupture: what direction for the next pope?
-
Surridge scores four as Nashville smash seven past Chicago
-
Chinese tea hub branches into coffee as tastes change
-
Diplomacy likely to trump geography in choice of new pope
-
All eyes turn to conclave after Pope Francis's funeral
-
Doves, deaths and rations: Papal elections over time
-
Progressive Canadians say social issues blown off election agenda
-
Liverpool primed for Premier League title party
-
Buenos Aires bids farewell to Francis with tears, calls to action
-
Thunder sweep past Grizzlies in NBA playoffs, Cavs on brink
-
Major blast at Iran port kills 14, injures 750
-
'What we live for': Kounde after winning Barca Copa del Rey final
-
More McIlroy magic at PGA pairs event but Novak and Griffin lead
-
Fire rages after major blast at Iran port kills 14, injures 750
-
Denkey wonder-strike keeps Cincinnati on track in MLS
-
Barca edge Real Madrid in extra-time to win wild Copa del Rey final
-
'Legendary' Eubank Jr beats Benn in grudge bout
-
Thunder sweep past Grizzlies into NBA playoffs 2nd round, Cavs on brink
-
South Korea's Ryu and Japan's Saigo share LPGA Chevron lead
-
Canada leaders make closing pitches in campaign upended by Trump
-
De Bruyne's Man City exit 'so difficult' for Guardiola
-
'No regrets' for Amorim over Man Utd move
-
Lyon and Strasbourg win to close in on Europe, Montpellier relegated from Ligue 1
-
Toulouse thrash Castres as Top 14 pursuers stumble
-
Djokovic crashes to nervous Arnaldi in Madrid opener, Swiatek advances
-
Olympic champs Russell, Davis-Woodhall win at Drake Relays
-
Browns end Sanders long draft slide
-
Cavs crush Heat, on brink of NBA playoff sweep
-
Fire rages after major blast at Iran port kills 8, injures hundreds
-
Kiwi Beamish wins Penn Relays 1,500m crown with late kick
-
Mbappe on Real Madrid bench for Clasico Copa del Rey final
-
England survive France fightback to seal Women's 6 Nations slam
-
Palace sweep past Villa to reach FA Cup final
-
CAF appoint Moroccan Lekjaa first vice-president
-
Major blast at Iran port kills 5, injures hundreds
-
Rodgers vows to stay with Celtic after fourth successive Scottish title
-
Ipswich relegated as Newcastle, Chelsea boost top five bids
-
Canada leaders make final pitches in campaign upended by Trump
-
Mullins -- Ireland's national training treasure
-
US, Iran say progress in 'positive' nuclear talks

'Remarkable global progress': HIV cases and deaths declining
The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.
But HIV is far from being stamped out, health experts warn ahead of World AIDS Day on Sunday.
- Uneven progress -
During the 2010s, the number of HIV infections across the world declined by a fifth, according to a major study published in The Lancet HIV journal on Tuesday.
Deaths related to HIV, which are generally caused by other diseases during the late stages of AIDS, fell by about 40 percent to below a million a year, the study said.
The decline was mainly driven by improving rates in sub-Saharan Africa, which is by far the hardest-hit region in the global epidemic.
However infections did not go down everywhere. Other regions, such as Eastern Europe and the Middle East, saw HIV numbers increase.
And the world remains far from the United Nations target of virtually eradicating AIDS-related deaths by 2030, the researchers said.
"The world has made remarkable global progress to significantly reduce the number of new HIV infections," said lead study author Hmwe Kyu of the US-based Institute For Health Metrics and Evaluation.
"More than a million people acquire a new HIV infection each year and, of the 40 million people living with HIV, a quarter are not receiving treatment," she said in a statement.
- Effective tools -
Preventative treatments called Pre-Exposure Prophylaxis (PrEP) have proven to be a powerful tool in the fight against HIV.
These daily pills reduce the risk of getting HIV from sex by around 99 percent.
They have helped drive down HIV rates in many countries. In some, such as France, health authorities are urging PrEP to be made more available to more people, rather than just men who have sex with men.
"It is something that can be used by anyone who needs it at some point in their sexual life," French infectious disease specialist Pierre Delobel told a press conference.
For people who have been infected with HIV, antiretroviral therapy can reduce the amount of the virus in their blood to undetectable levels.
An undetectable viral load means that there is less than a one percent chance that breastfeeding mothers pass HIV onto their babies, according to the US Centers for Disease Control and Prevention.
- New drug raises hopes -
These tools have worked well in wealthier countries but the high costs have meant that poorer countries -- such as in Africa -- have often been left behind.
There are fears that this history could repeat for a new drug that has been hailed as a potential game-changer in the battle against HIV.
Early trials have found that the antiretroviral treatment lenacapavir is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to administer than current regimens requiring daily pills.
US pharmaceutical giant Gilead has been charging around $40,000 per person per a year for the treatment in several countries.
But researchers have estimated the drug could be made for as little as $40, calling on Gilead to allow for cheaper access in hard-hit nations.
Last month, Gilead announced it had signed licensing deals with six generic drugmakers to produce and sell lenacapavir in lower-income countries.
While experts largely welcomed the move, some noted that millions of people with HIV live in countries not included in the deal.
The twice-yearly injection is also hoped to help get around another problem for administering HIV drugs -- the stigma that comes along with having the disease.
- What about a vaccine? -
Despite decades of effort, a vaccine for HIV remains elusive.
But the lenacapavir shot is "like having a vaccine basically", Andrew Hill, a researcher at the UK's Liverpool University, told AFP earlier this year.
A handful of patients have also been effectively cured of HIV.
But these cures happen only after a patient endures a brutal stem cell transplant for their leukaemia, so is not an option for almost all people living with HIV.
F.Dubois--AMWN